27791362|t|Nontoxic Formulations of Scintillation Nanocrystals for Use as X-ray Computed Tomography Contrast Agents
27791362|a|X-ray computed tomography (CT) is currently one of the most powerful, noninvasive, clinical in vivo imaging techniques, which has resulted from advances in both X-ray device and contrast enhancement technologies. The present study demonstrates, for the first time, that metal tungstates (such as CaWO4) are promising contrast agents for X-ray, radiation, and CT imaging, because of the high X-ray mass attenuation of tungsten (W). We have developed a method of formulation, in which CaWO4 (CWO) nanoparticles (NPs) are encapsulated within a biocompatible poly(ethylene glycol-b-d,l-lactic acid) (PEG-PLA) block copolymer (BCP) capsule. We show that these PEG-PLA - encapsulated CWO NPs (170 ± 10 nm hydrodynamic diameter) produce a higher CT contrast (by a factor of about 2) than commercial iodine -based radiocontrast agents (e.g., Iohexol) at identical molar concentrations of W or I atoms. PEG-PLA - coated CWO NPs are chemically stable and completely nontoxic. It was confirmed that the maximum tolerated dose (MTD) of this material in mice is significantly higher (250 ± 50 mg per kg body weight following a single intravenous (IV) administration) than, for instance, commercially available dextran - coated iron oxide nanoparticles that are currently used clinically as MRI contrast agents (MTD in mice ≈ 168 mg/kg per dose IV). IV- injected PEG-PLA / CWO NPs caused no histopathologic damage in major excretory organs (heart, liver, lungs, spleen, and kidney). When an IV dose of 100 mg/kg was given to mice, the blood circulation half-life was measured to be about 4 h, and more than 90% of the NPs were cleared from the mice within 24 h via the renal and hepatobiliary systems. When intratumorally administered, PEG-PLA - coated CWO NPs showed complete retention in a tumor-bearing mouse model (measurements were made up to 1 week). These results suggest that PEG-PLA - coated CWO NPs are promising materials for use in CT contrast.
27791362	63	88	X-ray Computed Tomography	T058	UMLS:C0040405
27791362	89	104	Contrast Agents	T103	UMLS:C0009924
27791362	105	130	X-ray computed tomography	T058	UMLS:C0040405
27791362	132	134	CT	T058	UMLS:C0040405
27791362	175	186	noninvasive	T170	UMLS:C2986496
27791362	197	204	in vivo	T082	UMLS:C1515655
27791362	205	223	imaging techniques	T058	UMLS:C0079595
27791362	266	278	X-ray device	T074	UMLS:C0183263
27791362	292	316	enhancement technologies	T058	UMLS:C0969683
27791362	330	335	study	T062	UMLS:C2603343
27791362	375	391	metal tungstates	T103	UMLS:C0077513
27791362	401	406	CaWO4	T103	UMLS:C0054486
27791362	422	437	contrast agents	T103	UMLS:C0009924
27791362	442	447	X-ray	T058	UMLS:C0043299
27791362	464	474	CT imaging	T058	UMLS:C0040405
27791362	496	501	X-ray	T058	UMLS:C0043299
27791362	522	530	tungsten	T103	UMLS:C0041383
27791362	532	533	W	T103	UMLS:C0041383
27791362	588	593	CaWO4	T103	UMLS:C0054486
27791362	595	598	CWO	T103	UMLS:C0054486
27791362	660	739	poly(ethylene glycol-b-d,l-lactic acid) (PEG-PLA) block copolymer (BCP) capsule	T103	UMLS:C0257395
27791362	760	767	PEG-PLA	T103	UMLS:C0257395
27791362	844	846	CT	T058	UMLS:C0040405
27791362	897	903	iodine	T103	UMLS:C0021968
27791362	911	931	radiocontrast agents	T103	UMLS:C0009924
27791362	939	946	Iohexol	T103	UMLS:C0022005
27791362	985	986	W	T103	UMLS:C0041383
27791362	990	991	I	T103	UMLS:C0021968
27791362	992	997	atoms	T103	UMLS:C0567415
27791362	999	1006	PEG-PLA	T103	UMLS:C0257395
27791362	1146	1150	mice	T204	UMLS:C0026809
27791362	1226	1257	intravenous (IV) administration	T082	UMLS:C0013125
27791362	1302	1309	dextran	T103	UMLS:C0086140
27791362	1319	1329	iron oxide	T103	UMLS:C0060240
27791362	1382	1385	MRI	T058	UMLS:C0024485
27791362	1386	1401	contrast agents	T103	UMLS:C0009924
27791362	1410	1414	mice	T204	UMLS:C0026809
27791362	1454	1461	PEG-PLA	T103	UMLS:C0257395
27791362	1479	1481	no	T033	UMLS:C1513916
27791362	1482	1497	histopathologic	T091	UMLS:C0677043
27791362	1514	1530	excretory organs	T017	UMLS:C0178784
27791362	1532	1537	heart	T017	UMLS:C0018787
27791362	1539	1544	liver	T017	UMLS:C0023884
27791362	1546	1551	lungs	T017	UMLS:C0024109
27791362	1553	1559	spleen	T017	UMLS:C0037993
27791362	1565	1571	kidney	T017	UMLS:C0022646
27791362	1616	1620	mice	T204	UMLS:C0026809
27791362	1626	1643	blood circulation	T038	UMLS:C0005775
27791362	1735	1739	mice	T204	UMLS:C0026809
27791362	1760	1765	renal	T017	UMLS:C0022646
27791362	1770	1791	hepatobiliary systems	T022	UMLS:C1711359
27791362	1827	1834	PEG-PLA	T103	UMLS:C0257395
27791362	1883	1908	tumor-bearing mouse model	T038	UMLS:C2986594
27791362	1975	1982	PEG-PLA	T103	UMLS:C0257395
27791362	2035	2037	CT	T058	UMLS:C0040405